Hummingbird Bioscience
The Galen, 61 Science Park Road, Singapore, 117525
Overview
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 7
Sector focus
- Biotechnology
- Health Care
- Oncology
- Therapeutics
Investment portfolio
- Hillstar Bio
Led · Series A · Mar 2025
Hillstar Bio develops next-generation precision immunology therapies that selectively deplete pathogenic immune cells while preserving healthy cells. Its lead program targets TRBV9+ T cells and is being advanced toward a clinical proof-of-concept study in axial spondyloarthritis and other HLA-B27-associated conditions. The company plans to initiate clinical trials for the TRBV9 program in 2026. Hillstar leverages tailored discovery techniques, validated technologies, and disease-specific biomarkers to identify patient populations and mitigate development risk. The company is backed by an investor syndicate and says it is fully funded through early clinical studies following the recent financing. Hillstar highlights a leadership team with deep expertise in antibody engineering, immunology, and clinical development.